Welcome to our dedicated page for Nakamoto SEC filings (Ticker: NAKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kindly MD, Inc. (NAKA) SEC filings page provides access to the company’s official regulatory disclosures as a publicly traded issuer. KindlyMD, a patient-first and healthcare data company with integrated healthcare services and a Bitcoin treasury strategy via its subsidiary Nakamoto Holdings Inc., uses filings with the U.S. Securities and Exchange Commission to report material events, corporate actions, and financial information.
Among the key documents available are Current Reports on Form 8-K, which the company uses to disclose significant developments. Recent 8-K filings have addressed topics such as the completion of the merger with Nakamoto, entry into and termination of material loan agreements secured by Bitcoin or other digital assets, authorization of a share repurchase program, receipt of a Nasdaq minimum bid price notice, and the establishment of dates and record dates for annual shareholder meetings. These filings also cover matters like redemption of a secured convertible debenture and the company’s financing arrangements with lenders focused on digital assets.
Investors can also review proxy materials, including the Definitive Proxy Statement on Schedule 14A, which outlines proposals submitted to stockholders, such as the election of directors, approval of converting Kindly MD from a Utah corporation to a Delaware corporation, ratification of the independent registered public accounting firm, and potential adjournment of the annual meeting. Notifications of late filing on Form 12b-25 (NT 10-Q) provide context when additional time is needed to complete quarterly reports, including explanations related to the accounting complexity of the merger with Nakamoto.
On Stock Titan, these filings are complemented by AI-powered tools that help summarize lengthy documents and highlight key points, such as new financing obligations, changes in capital structure, or updates on the company’s Bitcoin treasury strategy. Users can quickly locate information about quarterly and annual reporting, material agreements, shareholder votes, and listing status, as well as track how KindlyMD’s integrated healthcare operations and Bitcoin-focused activities are reflected in its regulatory record.
Kindly MD, Inc. filed a preliminary proxy for its 2025 Annual Meeting, to be held virtually on December 17, 2025 at 8:30 a.m. MT. Stockholders will vote on four proposals.
Proposal 1 seeks to elect two Class I directors—Perianne Boring and Greg Xethalis—for three-year terms. Proposal 2 requests approval to convert the company from a Utah corporation to a Delaware corporation. Proposal 3 asks stockholders to ratify Sadler Gibb & Associates as independent auditor for the fiscal year ended December 31, 2025. Proposal 4 authorizes potential adjournment to solicit additional proxies if needed.
The meeting is virtual at https://meeting.vstocktransfer.com/KINDLYDEC25. Holders of common stock as of the October 23, 2025 record date may vote. The Board recommends “FOR” all proposals. The proxy also outlines board independence, committee compositions, executive/Director biographies, compensation disclosures, and the company’s insider trading policy.
Kindly MD, Inc. (NAKA) director Eric Weiss filed an Initial Statement of Beneficial Ownership (Form 3) dated 08/14/2025. The filing lists Weiss's address in Salt Lake City, UT, confirms his status as a director, and states "No securities are beneficially owned." The form also references an Exhibit 24 - Power of Attorney and is signed by Eric Weiss.
Kindly MD, Inc., through its wholly owned subsidiary Naka SPV 2, LLC, entered into a Master Loan Agreement with Antalpha Digital Pte. Ltd. for a term loan facility of 206,000,000 USDT bearing interest at 7.0% per year. The loan will be funded in tranches over up to five days, with the first tranche of up to 150,000,000 USDT, and will mature 30 days after the initial tranche, with an option for a further 30‑day extension.
The facility is secured solely by Bitcoin or other agreed digital assets and includes customary covenants, loan‑to‑value requirements, representations, warranties, and events of default. Kindly MD plans to use the proceeds to fully repay its existing Master Loan Agreement with Two Prime Lending Limited and to cover related costs. The company also disclosed a non‑binding agreement to indicative terms with Antalpha for a potential issuance of up to $250,000,000 of secured convertible notes, subject to negotiation and definitive documentation.
Kindly MD, Inc. entered into a new term loan agreement through its subsidiary with Two Prime Lending Limited for $203,017,500 at 8.5% annual interest, maturing on September 30, 2026. The loan is secured by Bitcoin or other agreed digital assets and can be prepaid at any time without penalty.
The company used the loan proceeds to repay in full its secured convertible debenture held by a Yorkville-managed fund, making a cash payment of $203,000,000 plus $17,500 in reimbursed fees. This repayment terminates the debenture purchase agreement, related security documents (other than indemnification rights), and a registration rights agreement.
Separately, director Eric Weiss resigned from the board and governance committee, without any disagreement with the company, and the board named Mark Yusko as chair and Perianne Boring as a member of the nominating and corporate governance committee. Yusko will receive an additional annual cash fee of $25,000 for this committee role.
Kindly MD, Inc. reported that its board of directors set December 17, 2025 as the date for the company’s 2025 Annual Meeting of Stockholders, which will be held as a virtual meeting by live internet webcast. The board also set October 23, 2025 as the record date for determining which stockholders are entitled to receive notice of and vote at the meeting.
Because this meeting date is more than 30 days earlier than the prior annual meeting, the company established a new deadline of October 6, 2025 for receipt of qualified stockholder proposals and director nominations, including those seeking inclusion in the proxy materials under Rule 14a-8 and those subject to Rule 14a-19. The company also highlighted that material information about Kindly MD and its subsidiary Nakamoto Holdings may be provided through its and Nakamoto’s websites, SEC filings, press releases, and various social media accounts.
KindlyMD, Inc. filed a 424B7 prospectus listing numerous named selling stockholders who may offer shares of Common Stock registered for resale under the registration statement. The document states the applicable percentage figures are calculated using 413,603,091 shares of Common Stock outstanding as of September 24, 2025. The filing clarifies that the post-offering share amounts assume (a) all Common Stock underlying the Convertible Notes registered in this statement are sold and (b) no other transactions occur before completion of the offering, but also notes each selling stockholder may sell all, some or none of the shares and may use other registration statements or exemptions such as Rule 144.
Jared Barrera, Chief Financial Officer of Kindly MD, Inc. (NAKA), reported a restricted stock award that fully vested on 09/22/2025, resulting in an acquisition of 6,400 shares at no cash price and increasing his beneficial ownership to 22,242 shares. The Form 4, filed by attorney-in-fact on 09/24/2025, shows the transaction was an internal equity award rather than an open-market purchase or sale. The filing includes a standard Exhibit 24 power of attorney signature and does not disclose any cash consideration, option exercises, or derivative transactions.
Kindly MD, Inc. (NAKA) insider reported multiple grants to Chief Medical Officer Timothy Pickett on 09/22/2025. The Form 4 shows four non‑derivative transactions reporting the receipt of 37,593 restricted stock units that vest over four years with a 12‑month cliff, plus three fully vested restricted stock awards of 26,129, 10,146, and 18,378 shares, bringing reported beneficial ownership to 191,271 shares after the transactions. All grants were reported with a $0 price, indicating they are equity awards rather than market purchases. The filing is signed by an attorney‑in‑fact on behalf of the reporting person.
Eric Stanton Weiss, a director of Kindly MD, Inc. (NAKA), was granted 112,781 restricted stock units (RSUs) reported on a Form 4 with a transaction date of 09/22/2025. The RSUs were recorded at a price of $0 and are shown as directly beneficially owned following the grant. The RSUs vest on August 15, 2026 and are subject to Mr. Weiss’s continued service on the company’s board through that Vesting Date. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact, Kyle Simon, on 09/24/2025.
Kindly MD, Inc. (NAKA) director Gregory Elias Xethalis was reported as the sole reporting person on a Form 4 disclosing an award of 112,781 restricted stock units (RSUs) on 09/22/2025. The RSUs are non‑cash, granted at $0 price and are scheduled to vest on August 15, 2026, subject to his continued service on the board through the vesting date. After the reported transaction the filing shows 112,781 shares beneficially owned by the reporting person. The Form is signed by an attorney‑in‑fact on behalf of the reporting person on 09/24/2025.